{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:00:23Z","timestamp":1790258423377,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["30719"],"award-info":[{"award-number":["30719"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01586-4","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:38:12Z","timestamp":1786178292000},"page":"1067-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review"],"prefix":"10.1007","volume":"46","author":[{"given":"Mohammad","family":"Alimoradnori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abutorabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhdeh","family":"Zabihiyeganeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Arabloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Jahanghiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"1","key":"1586_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11657-024-01447-7","volume":"19","author":"M Li","year":"2024","unstructured":"Li M, Ge Z, Zhang B, et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024;19(1):89. https:\/\/doi.org\/10.1007\/s11657-024-01447-7.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"1586_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39(2):181\u2013209. https:\/\/doi.org\/10.1007\/s40273-020-00965-9.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1586_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.11005\/jbm.2023.30.1.37","volume":"30","author":"M Rajabi","year":"2023","unstructured":"Rajabi M, Ostovar A, Sari AA, et al. Health-related quality of life in osteoporosis patients with and without fractures in Tehran, Iran. J Bone Metab. 2023;30(1):37\u201346. https:\/\/doi.org\/10.11005\/jbm.2023.30.1.37.","journal-title":"J Bone Metab"},{"issue":"4","key":"1586_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40273-022-01239-2","volume":"41","author":"N Li","year":"2023","unstructured":"Li N, Beaudart C, Cauley JA, et al. Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review. Pharmacoeconomics. 2023;41(4):363\u201391. https:\/\/doi.org\/10.1007\/s40273-022-01239-2.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1586_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73068","volume":"16","author":"S Nunkoo","year":"2024","unstructured":"Nunkoo S, Krissheeven M, Chitravanshi A, et al. Clinical efficacy and safety of teriparatide versus alendronate in postmenopausal osteoporosis: a systematic review of randomized controlled trials. Cureus. 2024;16(11):e73068. https:\/\/doi.org\/10.7759\/cureus.73068.","journal-title":"Cureus"},{"issue":"2","key":"1586_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","volume":"31","author":"L Tabatabai","year":"2025","unstructured":"Tabatabai L, Cosman F, Curtis JR, et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract. 2025;31(2):159\u201368. https:\/\/doi.org\/10.1016\/j.eprac.2024.10.017.","journal-title":"Endocr Pract"},{"key":"1586_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102425","volume":"68","author":"YX Han","year":"2024","unstructured":"Han YX, Mo YY, Wu HX, et al. Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine. 2024;68:102425. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102425.","journal-title":"EClinicalMedicine"},{"key":"1586_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101689","volume":"18","author":"MG Soroush","year":"2023","unstructured":"Soroush MG, Kheirandish M, Soroosh S. Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: a single-arm, multi-center study. Bone Rep. 2023;18:101689. https:\/\/doi.org\/10.1016\/j.bonr.2023.101689.","journal-title":"Bone Rep."},{"issue":"1","key":"1586_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-05348-9","volume":"24","author":"Y Zarinfar","year":"2024","unstructured":"Zarinfar Y, Panahi N, Hosseinpour M, et al. The association between osteoporosis and quality of life among older adults in Southern Iran: findings from the Bushehr Elderly Health Program. BMC Geriatr. 2024;24(1):766. https:\/\/doi.org\/10.1186\/s12877-024-05348-9.","journal-title":"BMC Geriatr"},{"issue":"1","key":"1586_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00774-024-01536-0","volume":"43","author":"K Ebina","year":"2025","unstructured":"Ebina K, Etani Y, Noguchi T, et al. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2025;43(1):3\u20139. https:\/\/doi.org\/10.1007\/s00774-024-01536-0.","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1586_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07227-1","volume":"25","author":"M Kong","year":"2024","unstructured":"Kong M, Gao C, Luan X, et al. Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2024;25(1):109. https:\/\/doi.org\/10.1186\/s12891-024-07227-1.","journal-title":"BMC Musculoskelet Disord"},{"key":"1586_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/abr.abr_127_22","volume":"12","author":"M Hosseini Khameneh","year":"2023","unstructured":"Hosseini Khameneh M, Gorji M, Jafari Kafi-Ababdi M, et al. Effects of teriparatide on clinical and radiologic long-term outcomes after fixation of pertrochanteric hip fractures. Adv Biomed Res. 2023;12:139. https:\/\/doi.org\/10.4103\/abr.abr_127_22.","journal-title":"Adv Biomed Res"},{"key":"1586_CR13","unstructured":"The Campbell and Cochrane Economics Methods Group (CCEMG) & Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre). 2019 CCEMG-EPPI-Centre Cost Converter. Available from: https:\/\/eppi.ioe.ac.uk\/costconversion\/. Accessed 2 Aug 2026."},{"issue":"3","key":"1586_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/2325967120987241","volume":"9","author":"CA Primeau","year":"2021","unstructured":"Primeau CA, Zomar BO, Somerville LE, et al. Health economic evaluations of hip and knee interventions in orthopaedic sports medicine: a systematic review and quality assessment. Orthop J Sports Med. 2021;9(3):2325967120987241. https:\/\/doi.org\/10.1177\/2325967120987241.","journal-title":"Orthop J Sports Med"},{"key":"1586_CR15","doi-asserted-by":"publisher","DOI":"10.14196\/mjiri.31.39","author":"AA Ebadi Fard Azar","year":"2017","unstructured":"Ebadi Fard Azar AA, Rezapour A, Alipour V, et al. Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran. Med J Islam Repub Iran. 2017. https:\/\/doi.org\/10.14196\/mjiri.31.39.","journal-title":"Med J Islam Repub Iran"},{"issue":"3","key":"1586_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3111\/13696998.2010.499072","volume":"13","author":"F Borgstrom","year":"2010","unstructured":"Borgstrom F, Strom O, Marin F, et al. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ. 2010;13(3):381\u201392. https:\/\/doi.org\/10.3111\/13696998.2010.499072.","journal-title":"J Med Econ"},{"key":"1586_CR17","doi-asserted-by":"publisher","unstructured":"Martinez JPD, de Maraumont TA, S\u00e1nchez EN, et al. Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. medRxiv. 2024:2024.02.16.24302926. https:\/\/doi.org\/10.1101\/2024.02.16.24302926.","DOI":"10.1101\/2024.02.16.24302926"},{"issue":"7","key":"1586_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00198-024-07043-2","volume":"35","author":"E Gielen","year":"2024","unstructured":"Gielen E, Aldven M, Kanis JA, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int. 2024;35(7):1173\u201383. https:\/\/doi.org\/10.1007\/s00198-024-07043-2.","journal-title":"Osteoporos Int"},{"issue":"10","key":"1586_CR19","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00198-021-05927-1","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Tanaka K, Silverman S, et al. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int. 2021;32(10):2011\u201321. https:\/\/doi.org\/10.1007\/s00198-021-05927-1.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1586_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, et al. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019;49(2):184\u201396. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.006.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1586_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40520-023-02682-7","volume":"36","author":"M Hiligsmann","year":"2024","unstructured":"Hiligsmann M, Silverman SL, Singer AJ, et al. Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clin Exp Res. 2024;36(1):14. https:\/\/doi.org\/10.1007\/s40520-023-02682-7.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"1586_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA, Hay JW, Becker R, et al. Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother. 2019;53(2):134\u201343. https:\/\/doi.org\/10.1177\/1060028018798034.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1586_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/GME.0000000000001339","volume":"26","author":"N Li","year":"2019","unstructured":"Li N, Zheng B, Liu M, et al. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. Menopause. 2019;26(8):906\u201314. https:\/\/doi.org\/10.1097\/GME.0000000000001339.","journal-title":"Menopause"},{"issue":"11","key":"1586_CR24","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","volume":"166","author":"H Liu","year":"2006","unstructured":"Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166(11):1209\u201317. https:\/\/doi.org\/10.1001\/archinte.166.11.1209.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1586_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40618-022-01910-7","volume":"46","author":"C Luo","year":"2023","unstructured":"Luo C, Qin SX, Wang QY, et al. Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. J Endocrinol Invest. 2023;46(2):367\u201379. https:\/\/doi.org\/10.1007\/s40618-022-01910-7.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1586_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00223-016-0132-8","volume":"99","author":"A Marques","year":"2016","unstructured":"Marques A, Lourenco O, Ortsater G, et al. Cost-effectiveness of intervention thresholds for the treatment of osteoporosis based on FRAX\u00ae in Portugal. Calcif Tissue Int. 2016;99(2):131\u201341. https:\/\/doi.org\/10.1007\/s00223-016-0132-8.","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"1586_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10233","volume":"3","author":"T Mori","year":"2019","unstructured":"Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of sequential teriparatide\/alendronate versus alendronate-alone strategies in high-risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide. JBMR Plus. 2019;3(11):e10233. https:\/\/doi.org\/10.1002\/jbm4.10233.","journal-title":"JBMR Plus"},{"issue":"1","key":"1586_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00891-z","volume":"6","author":"T Mori","year":"2021","unstructured":"Mori T, Crandall CJ, Fujii T, et al. Cost-effectiveness of sequential daily teriparatide\/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch Osteoporos. 2021;6(1):72. https:\/\/doi.org\/10.1007\/s11657-021-00891-z.","journal-title":"Arch Osteoporos"},{"issue":"6","key":"1586_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00019053-200826060-00005","volume":"26","author":"D Mueller","year":"2008","unstructured":"Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics. 2008;26(6):513\u201336. https:\/\/doi.org\/10.2165\/00019053-200826060-00005.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1586_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-213","volume":"3","author":"DR Murphy","year":"2012","unstructured":"Murphy DR, Smolen LJ, Klein TM, et al. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord. 2012;3(1):213. https:\/\/doi.org\/10.1186\/1471-2474-13-213.","journal-title":"BMC Musculoskelet Disord"},{"key":"1586_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/math9182331","volume":"18","author":"M Osca-Guadalajara","year":"2021","unstructured":"Osca-Guadalajara M, D\u00edaz-Carnicero J, Gonz\u00e1lez-de-Juli\u00e1n S, et al. Markov models for economic evaluation in osteoporosis treatment. Mathematics (Basel). 2021;18:2331. https:\/\/doi.org\/10.3390\/math9182331.","journal-title":"Mathematics (Basel)"},{"issue":"2","key":"1586_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.22037\/ijpr.2019.1100679","volume":"18","author":"S Taheri","year":"2019","unstructured":"Taheri S, Mirzayeh Fashami F, Peiravian F, et al. Teriparatide in the treatment of severe postmenopausal osteoporosis: a cost-utility Aaalysis. Iran J Pharm Res. 2019;18(2):1073\u20135. https:\/\/doi.org\/10.22037\/ijpr.2019.1100679.","journal-title":"Iran J Pharm Res."},{"issue":"1","key":"1586_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-023-01309-8","volume":"18","author":"L Tian","year":"2023","unstructured":"Tian L, Luo C, Li YF, et al. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. Arch Osteoporos. 2023;18(1):100. https:\/\/doi.org\/10.1007\/s11657-023-01309-8.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"1586_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GME.0000000000001911","volume":"29","author":"R You","year":"2021","unstructured":"You R, Mori T, Ke L, et al. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China. Menopause. 2021;29(2):210\u20138. https:\/\/doi.org\/10.1097\/GME.0000000000001911.","journal-title":"Menopause"},{"key":"1586_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.794861","volume":"10","author":"R You","year":"2022","unstructured":"You R, Liu J, Ke L, et al. Cost-effectiveness of sequential teriparatide\/zoledronic acid compared with zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Front Public Health. 2022;10:794861. https:\/\/doi.org\/10.3389\/fpubh.2022.794861.","journal-title":"Front Public Health"},{"key":"1586_CR36","doi-asserted-by":"publisher","first-page":"21050001","DOI":"10.14456\/sehs.2021.10","volume":"15","author":"E Wiroonpochit","year":"2021","unstructured":"Wiroonpochit E, Kapol N, Lochid-Amnuay S, et al. Cost-utility analysis of drugs for secondary bone fracture prevention among post-menopausal osteoporotic patients in Thailand. Sci Eng Health Stud. 2021;15:21050001. https:\/\/doi.org\/10.14456\/sehs.2021.10.","journal-title":"Sci Eng Health Stud."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01586-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01586-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01586-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:51Z","timestamp":1790255631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01586-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01586-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mohammad Alimoradnori, Ali Abutorabi, Mozhdeh Zabihiyeganeh, Jalal Arabloo, and Reza Jahanghiri have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Iran University of Medical Sciences, Iran (Code: IR.IUMS.REC.1402.1206).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary materials.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conception or design of the work: AA and MA. Preliminary search: MA and JA. Data analysis and interpretation AA, MA, and JA. Original draft preparation: MA, AA, and JA. Critical revision and editing of the manuscript: MZ and RJ. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}